28 studies found for:    "Systemic mastocytosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis (ASM);   Systemic Mastocytosis With Associated Clonal Hematological Non-mast Cell Lineage Disease (SM-AHNMD);   Mast Cell Leukemia (MCL);   Smoldering Systemic Mastocytosis (SSM);   Indolent Systemic Mastocytosis (ISM) [ISM Subgroup Fully Recruited]
Intervention: Other: Interview
2 Recruiting Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis;   Associated Clonal Hematological Non-Mast-Cell Lineage Disease
Interventions: Drug: Ibrutinib;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Active, not recruiting Treatment of Indolent Systemic Mastocytosis With PA101
Conditions: Mastocytosis;   Systemic Mastocytosis;   Indolent Systemic Mastocytosis
Interventions: Drug: PA101;   Drug: Placebo
4 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
5 Recruiting Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Conditions: Aggressive Systemic Mastocytosis;   Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease;   Mast Cell Leukemia;   Relapsed or Refractory Myeloid Malignancies
Intervention: Drug: BLU-285
6 Terminated
Has Results
Obatoclax for Systemic Mastocytosis
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Obatoclax Mesylate
7 Completed Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Ontak (Denileukin Diftitox)
8 Completed
Has Results
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: RAD001 (Everolimus)
9 Recruiting Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
10 Active, not recruiting Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
11 Recruiting Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Procedure: Mastocytosis diagnosis
12 Active, not recruiting Midostaurin in Indolent Systemic Mastocytosis
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: Midostaurin,
13 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
14 Active, not recruiting
Has Results
Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Conditions: Systemic Mastocytosis, Aggressive (ASM);   Leukemia, Mast Cell;   Hematological Non-mast Cell Lineage Disease (AHNMD)
Intervention: Drug: Midostaurin
15 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
16 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
17 Unknown  Evaluation of Response of Dasatinib to Treat Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Dasatinib
18 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: AK002
19 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
20 Recruiting A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Conditions: Gastrointestinal Stromal Tumors;   Aggressive Systemic Mastocytosis;   Advanced Cancers
Intervention: Drug: DCC-2618

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Indicates status has not been verified in more than two years